Professor Griffin obtained his DPhil from the University of Oxford, studying brain biochemistry using 13C NMR spectroscopy in the lab of Sir. Prof. George Radda. He worked as a Harvard Medical School/Massachusetts General Hospital Fellow in Radiology, applying 13C NMR to cardiac metabolism and then as a post-doctoral researcher in the lab of Prof. Jeremy Nicholson at Imperial College London developing metabonomic tools for environmental toxicology. He took up a Royal Society University Research Fellowship at Imperial College and then moved to the Department of Biochemistry, University of Cambridge as a group leader. He was a group leader at MRC Human Nutrition Research and Professor of Metabolism and Nutrition at the University of Cambridge. In 2019 he moved to Imperial College to take up the Chair of Biological Chemistry and head up the Section of Biomolecular Medicine in the Department of Metabolism, Digestion and Reproduction.
His group’s research is focused on understanding how diet interacts with the relative risk of developing metabolic diseases, and, in particular, the use of metabolomics and lipidomics to understand the underlying mechanisms of disease. The group makes use of cell culture, animal studies, human intervention trials and human cohort studies to explore these mechanisms. He is the President of the Metabolomics Society, director of the Metabolic Profiling Forum and a recipient of an Agilent Thought Leader Award in lipidomics.
Professor Griffin’s research is funded by the MRC, EU 2020, the Wellcome Trust, the BBSRC, Alzheimer’s Research UK, the Alzheimer’s Society and NIHR.
et al., 2021, Metabolic phenotyping and cardiovascular disease: Overview of evidence from epidemiological settings, Heart, Vol:107, ISSN:1355-6037, Pages:1123-1129
et al., 2021, Suppression of insulin-induced gene 1 (INSIG1) function promotes hepatic lipid remodelling and restrains NASH progression, Molecular Metabolism, Vol:48, ISSN:2212-8778, Pages:1-10
et al., 2021, Pathway-based integration of multi-omics data reveals lipidomics alterations validated in an Alzheimer’s Disease mouse model and risk loci carriers
et al., 2021, Metabolomic analysis in inflammatory bowel disease: a systematic review, Journal of Crohns & Colitis, Vol:15, ISSN:1873-9946, Pages:813-826
et al., 2021, Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer, Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), WILEY, Pages:337A-338A, ISSN:0270-9139